{"id":"f2e06f59-2508-5fb2-922a-f06bacaed392","stable_key":"cfa4bd86-d88d-555a-975c-68877bf00e0f:lutein-cataract-low-intake","predicate":"associated_with_lower","statement":"In the lowest dietary L+Z quintile, cataract-surgery HR was 0.68 (95% CI 0.48–0.96; P=0.03).","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"b8270785-392c-5942-b6dc-73cceb7df077","mechanism_event_label":"A subgroup with lower intake had a favorable estimate.","subject":{"id":"686d1ca5-d766-59f5-97ce-6cedbd46c761","slug":"human-lutein-zeaxanthin-10-2","display_name":"Lutein 10 mg plus zeaxanthin 2 mg daily combination","entity_type_key":"chemical_species"},"object":{"id":"426c7f55-a801-5a77-bfa4-9b2ed890f27d","slug":"human-cataract-surgery","display_name":"Cataract surgery occurrence","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"b8270785-392c-5942-b6dc-73cceb7df077","stable_key":"cfa4bd86-d88d-555a-975c-68877bf00e0f:lutein-cataract-low-intake-event","event_type":"observed_intervention","label":"A subgroup with lower intake had a favorable estimate.","description":"In the lowest dietary L+Z quintile, cataract-surgery HR was 0.68 (95% CI 0.48–0.96; P=0.03).","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4478c496-5293-5e0b-a0d0-1aa3b6df0ec1","slug":"areds2-low-dietary-lz","display_name":"AREDS2 lowest quintile of dietary lutein/zeaxanthin intake","entity_type_key":"chemical_species"},"role":"intake_context","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"5dd84367-3f8e-5a3f-b952-a96174ea51fa","slug":"lutein","display_name":"Lutein","entity_type_key":"small_molecule"},"role":"combination_component","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"0a60c685-7502-5ece-9da2-2c1a2e3bcdf1","slug":"zeaxanthin","display_name":"Dietary (3R,3-prime-R)-zeaxanthin","entity_type_key":"small_molecule"},"role":"combination_component","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"686d1ca5-d766-59f5-97ce-6cedbd46c761","slug":"human-lutein-zeaxanthin-10-2","display_name":"Lutein 10 mg plus zeaxanthin 2 mg daily combination","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"426c7f55-a801-5a77-bfa4-9b2ed890f27d","slug":"human-cataract-surgery","display_name":"Cataract surgery occurrence","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/lutein-research/23645227.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"3e75988c75dde9e6525246ae68335c49c03c31f02c7419dcf74110966b7dce32\", \"start_char\": 0, \"end_char\": 2245, \"text_sha256\": \"3e75988c75dde9e6525246ae68335c49c03c31f02c7419dcf74110966b7dce32\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"AREDS2 cataract secondary outcome and dietary subgroup analysis","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"L+Z 10/2 mg daily; median 4.7 years","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Lowest-intake subgroup is not a clinical deficiency diagnosis; overall and subgroup results must stay separate.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Lutein research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"lutein","display_name":"Lutein","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"3159 participants phakic in at least one eye","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A subgroup with lower intake had a favorable estimate.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[lutein-p23645227] Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. (2013). https://pubmed.ncbi.nlm.nih.gov/23645227/ DOI: 10.1001/jamaophthalmol.2013.4412","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"6027 study eyes","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"71b775ff-46fa-50c7-a44b-6049fdc0ac81","evidence_kind":"source_excerpt","locator":"Lines 827-838","start_line":827,"end_line":838,"excerpt":"### lutein-cataract-low-intake\nIn the lowest dietary L+Z quintile, cataract-surgery HR was 0.68 (95% CI 0.48–0.96; P=0.03).\nCondition category: biomarker_context\nnutrient_topic: Lutein research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: A subgroup with lower intake had a favorable estimate.\norganism: 3159 participants phakic in at least one eye\ntissue_or_cell_type: 6027 study eyes\nexperimental_model: AREDS2 cataract secondary outcome and dietary subgroup analysis\nlimitations: Lowest-intake subgroup is not a clinical deficiency diagnosis; overall and subgroup results must stay separate.\nexposure: L+Z 10/2 mg daily; median 4.7 years\nevidence_span: {\"source_cache\": \"artifacts/lutein-research/23645227.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"3e75988c75dde9e6525246ae68335c49c03c31f02c7419dcf74110966b7dce32\", \"start_char\": 0, \"end_char\": 2245, \"text_sha256\": \"3e75988c75dde9e6525246ae68335c49c03c31f02c7419dcf74110966b7dce32\"}\n[lutein-p23645227] Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. (2013). https://pubmed.ncbi.nlm.nih.gov/23645227/ DOI: 10.1001/jamaophthalmol.2013.4412","model_system":"AREDS2 cataract secondary outcome and dietary subgroup analysis","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [lutein-p23645227] Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. (2013). https://pubmed.ncbi.nlm.nih.gov/23645227/ DOI: 10.1001/jamaophthalmol.2013.4412","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"beef4241-6ebd-5b36-864c-6ef3ed7e61b8","stable_key":"import-cfa4bd86-d88d-555a-975c-68877bf00e0f","title":"Lutein: metabolism, signaling and nutrient connections (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"1514ec459913a7044b4c4e1012ed367bcb918298181ebabd2a9e2ccecd789053","revision_id":"bae2c856-0785-546f-b08f-869318c27f9e","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}